Table 2.
Univariate logistic regression analysis of different variables predicting pCR in the training set
| P | OR | 95 % CI | |
|---|---|---|---|
| Total | |||
| Age | 0.385 | ||
| ≤40 years | 1 | ||
| >40 years | 0.385 | 0.767 | 0.423-1.394 |
| Menopausal status | 0.518 | ||
| Pre-menopausal | 1 | ||
| Post-menopausal | 0.518 | 0.843 | 0.502-1.416 |
| Tumor Size | 0.029 | ||
| T1 | 1 | ||
| T2 | 0.052 | 0.500 | 0.248-1.007 |
| T3 | 0.014 | 0.369 | 0.167-0.815 |
| T4 | 0.008 | 0.282 | 0.111-0.716 |
| Nodal status | 0.432 | ||
| N0 | 1 | ||
| N1 | 0.493 | 0.802 | 0.426-1.508 |
| N2 | 0.701 | 1.308 | 0.332-5.147 |
| N3 | 0.328 | 1.171 | 0.564-5.561 |
| Hormone receptor status | <0.001 | ||
| Negative | 1 | ||
| Positive | <0.001 | 0.307 | 0.182-0.518 |
| Regimens | <0.001 | ||
| Cyclophosphamide, epirubicin and 5-fluorouracil | 1 | ||
| Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin | 0.158 | 4.779 | 0.544-42.018 |
| Navelbine and epirubicin | 0.094 | 6.047 | 0.738-49.558 |
| Paclitaxel and carboplatin or paclitaxel and cisplatin | 0.006 | 16.479 | 2.236-121.451 |
| Cycles | 0.029 | ||
| 3-4 | 1 | ||
| 1-2 | 0.018 | 0.176 | 0.042-0.740 |
| 5-6 | 0.143 | 0.577 | 0.264-1.261 |
Abbreviations: pCR pathological complete response, OR odds ratio, CI confidence interval